A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
← catalyst calendarSponsored by WW International Inc (industry) · WW — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
226actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-18 | actual | When the study began enrolling |
| Primary completion | 2026-02-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-05 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Behavioral: WW Clinic
- Drug: Bupropion-Naltrexone
- Drug: Bupropion-Naltrexone-Metformin
Primary outcome
what the primary-completion date above is the date OFPercent body weight change at 12 weeks
measured Baseline, 12 weeks
Permalink · WW's whole pipeline · Catalyst calendar · Every registered study · What changed